Stock BOLT BOLT BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Bolt Biotherapeutics, Inc.

Equities

BOLT

US0977021049

Market Closed - Nasdaq
Other stock markets
 20:58:48 02/05/2024 BST 		5-day change 1st Jan Change
1.1 USD -1.79% Intraday chart for Bolt Biotherapeutics, Inc. -5.17% -1.79%
03-21 Bolt Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
03-21 Bolt Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Evolution of the average Target Price on Bolt Biotherapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

95be4bbd9c151.LHz-qUHrTjPRDL--l_o4Fw7AhXIN7W3IrWUP-u5rKJM.aTiOw3WiKHuVP_6Tosp7Rn2RtgdFpA6pwxJ7qIshT-RCN5eeCqEaBLZohw~47bf30d1682e50f58851c9062ad2a61d

Analyst Recommendations on Bolt Biotherapeutics, Inc.

SVB Securities Upgrades Bolt Biotherapeutics to Outperform From Market Perform, Price Target is $4 MT
Morgan Stanley Cuts Price Target on Bolt Biotherapeutics to $3 From $5, Maintains Equal-Weight Rating MT
HC Wainwright Starts Bolt Biotherapeutics at Buy With $8 Price Target MT
Stifel Nicolaus Lowers Price Target for Bolt Biotherapeutics to $7 From $13, Maintains Buy Rating MT
SVB Securities Downgrades Bolt Biotherapeutics to Market Perform from Outperform, Adjusts Price Target to $4 from $8 MT
Morgan Stanley Adjusts Bolt Biotherapeutics' Price Target to $5 from $7, Keeps Equalweight Rating MT
Stifel Adjusts Bolt Biotherapeutics' Price Target to $13 From $16, Reiterates Buy Rating MT
Morgan Stanley Adjusts Bolt Biotherapeutics' Price Target to $7 from $11, Keeps Equalweight Rating MT
Morgan Stanley Downgrades Bolt Biotherapeutics to Equalweight from Overweight, Adjusts Price Target to $11 from $45 MT
Stifel Adjusts Bolt Biotherapeutics' Price Target to $19 From $34, Reiterates Buy Rating MT
SVB Leerink Adjusts Price Target on Bolt Biotherapeutics to $33 from $35, Keeps Outperform Rating MT
BOLT BIOTHERAPEUTICS : SVB Leerink Raises Bolt Biotherapeutics' Price Target to $35 From $34, Maintains Outperform Rating MT
BOLT BIOTHERAPEUTICS : SVB Leerink Adjusts Price Target on Bolt Biotherapeutics to $37 From $36, Maintains Outperform Rating MT
BOLT BIOTHERAPEUTICS : Morgan Stanley Starts Bolt Biotherapeutics at Overweight With $45 Price Target MT
BOLT BIOTHERAPEUTICS : Stifel Starts Bolt Biotherapeutics at Buy With $40 Price Target MT
BOLT BIOTHERAPEUTICS : SVB Leerink Starts Bolt Biotherapeutics at Outperform With $36 Price Target MT
BOLT BIOTHERAPEUTICS : Guggenheim Starts Bolt Biotherapeutics at Buy With $42 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.12 USD
Average target price
4.45 USD
Spread / Average Target
+297.32%
High Price Target
8 USD
Spread / Highest target
+614.29%
Low Price Target
1.25 USD
Spread / Lowest Target
+11.61%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Bolt Biotherapeutics, Inc.

SVB Securities LLC
Morgan Stanley
HC Wainwright
Stifel Nicolaus
SVB Leerink
Guggenheim

Ratings for Bolt Biotherapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. BOLT Stock
  4. Consensus Bolt Biotherapeutics, Inc.